Every one of those 1 sits in a single category, markets. Cormorant Asset Management is most often covered alongside Olema Pharmaceuticals, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.5.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Cormorant Asset Management
Every one of those 1 sits in a single category, markets. Cormorant Asset Management is most often covered alongside Olema Pharmaceuticals, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.5. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. We currently track 1 Finance story that mention Cormorant Asset Management, all published on March 22, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 71 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Cormorant Asset Management. Shared-story counts are live from our verified record — not editorial picks.
Olema Pharmaceuticals (OLMA) has delivered a massive 242% return over the past year, fueled by clinical progress in its lead breast cancer candidate, palazestrant. A recent $122 million institutional position has sparked debate over whether the biotech firm still has significant room for growth ahead of a projected 2027 launch.